The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 2×
“Hence, isocyanoacetates 1, 2 and 3 gave the cyclic imidazoline product, while isocyanides 4, 5 and 6 showed the alpha-amino amide product.”
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Clinical and immunological features of severe and moderate coronavirus disease 2019
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · cited 5×
“Unlike DNA vaccines, mRNA vaccines only need to enter the cell’s cytoplasm to enable antigen expression, and there is no risk of genomic integration 6 .”
BackgroundInfluentialGrifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930 · cited 1×
“The mRNA constructs synthesized for this C3d study were chemically modified with pseudouridine, which allows for in vitro and in vivo protein translation and reduces innate immunogenicity 39,40 .”
MethodSARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
Le Bert, N., Tan, A. T., Kunasegaran, K., Tham, C. Y. L., Hafezi, M., Chia, A., Chng, M. H. Y., Lin, M., Tan, N., Linster, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2550-z · Cited by 1,887
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
Levin, E. G., Lustig, Y., Cohen, C., Fluss, R., Indenbaum, V., Amit, S., Doolman, R., Asraf, K., Mendelson, E., Ziv, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114583 · Cited by 1,703 · cited 1×
“1 are provided in the Supplementary Information.”
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity
Dempsey, P. W., Allison, M. E. D., Akkaraju, S., Goodnow, C. C., & Fearon, D. T. (1996) · Science · doi:10.1126/science.271.5247.348 · Cited by 1,197 · cited 3×
“Despite the advantageous, adjuvant effects of C3d shown in protein and DNA vaccine studies 58,62–68 , the incorporation of C3d in an mRNA vaccine has not been shown to date.”
Background
Cited by
Li, B., Raji, I. O., Gordon, A. G. R., Sun, L., Raimondo, T. M., Oladimeji, F. A., Jiang, A. Y., Varley, A., Langer, R. S., & Anderson, D. G. (2024) · Nature Materials · doi:10.1038/s41563-024-01867-3 · Cited by 305
“We, among others, have been exploring high-throughput synthesis (HTS) strategies to expedite the design and identification of new ionizable lipids for RNA delivery 15,16 .”
Self-citationHigh-density Lipoprotein Inspired Lipid Nanoparticles for Systemic RNA delivery to the Brain
Xu, Z., Shalin, K., Do, V., Yan, A., & Gao, J. (2026) · doi:10.64898/2026.05.29.728695 · Cited by 1
Engineering intramolecular adjuvants for next-generation vaccines
Wang, Y., Liao, W., Zhang, Z., Wang, T., Zhang, J., Zai, X., & Xu, J. (2026) · The Innovation Medicine · doi:10.59717/j.xinn-med.2026.100258
Metadata
- Authors
- Li, B., Jiang, A. Y., Raji, I., Atyeo, C., Raimondo, T. M., Gordon, A. G. R., Rhym, L. H., Samad, T., MacIsaac, C., Witten, J., Mughal, H., Chicz, T. M., Xu, Y., McNamara, R. P., Bhatia, S., Alter, G., Langer, R., & Anderson, D. G.
- Venue
- Nature Biomedical Engineering
- Published
- 2023-09-07
- Volume
- 9
- Issue
- 2
- Pages
- 167-184
- ISSN
- 2157-846X (ISSN-L)
- OpenAlex
- W4386495948
- Cited by
- 164
- References
- 31
- FWCI
- 12.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA. https://app.cochat.ai/papers/10.1038/s41551-023-01082-6
- The paper
- Li, B., Jiang, A. Y., Raji, I., Atyeo, C., Raimondo, T. M., Gordon, A. G. R., Rhym, L. H., Samad, T., MacIsaac, C., Witten, J., Mughal, H., Chicz, T. M., Xu, Y., McNamara, R. P., Bhatia, S., Alter, G., Langer, R., & Anderson, D. G. (2023). Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA. Nature Biomedical Engineering. https://doi.org/10.1038/s41551-023-01082-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.